Annexon Inc is a biotechnology business based in the US. Annexon Inc shares (ANNX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.02 – an increase of 11.61% over the previous week. Annexon Inc employs 71 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.02 |
|---|---|
| 52-week range | $1.57 - $8.40 |
| 50-day moving average | $6.12 |
| 200-day moving average | $5.43 |
| Wall St. target price | $16.40 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.02 from 2024-10-10
| 1 week (2024-10-04) | 11.61% |
|---|---|
| 1 month (2024-09-12) | 4.31% |
| 3 months (2024-07-12) | 15.46% |
| 6 months (2024-04-12) | 17.39% |
| 1 year (2023-10-12) | 322.89% |
|---|---|
| 2 years (2022-10-10) | 12.14% |
| 3 years (2021-10-12) | 21.18 |
| 5 years (2019-10-08) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -24.83% |
| Return on equity TTM | -42.2% |
| Profit margin | 0% |
| Book value | $3.42 |
| Market Capitalization | $728 million |
TTM: trailing 12 months
We're not expecting Annexon Inc to pay a dividend over the next 12 months.
Over the last 12 months, Annexon Inc's shares have ranged in value from as little as $1.57 up to $8.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Annexon Inc's is 1.279. This would suggest that Annexon Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Annexon, Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.